Jefferies Upgrades Chemed Stock to Buy Rating
Investors see a price target increase to $620 following the company's strong third-quarter results.
Updated on Oct. 28, 2026 in Stock Picks
Live Poll
Do you rely on analyst stock upgrades when making your own investment decisions?
Investment firm Jefferies upgraded Chemed stock to a buy rating while increasing its price target to $620 per share. The upgrade follows third-quarter earnings that surpassed analyst expectations and signs that the company has resolved prior operational issues.
Why it matters
Investors tracking healthcare equities may note that Chemed has addressed prior Medicare hospice cap issues that limited its income in 2025. The company's recent performance suggests a return to earnings growth, though market outcomes remain subject to analyst projections.
Jefferies raised its target price for Chemed to $620 from $520, representing a potential 22% increase from the prior close. The company shares rose more than 2% in premarket trading, following a 16% gain over the past year.
The players
Jefferies
An investment banking firm that provides research and financial services to institutional and individual investors.
Chemed
A company specializing in hospice and palliative care services that is currently under review by financial analysts.
The details
Jefferies analysts adjusted their rating after reviewing Chemed's recent operational performance and earnings visibility. The company appears to have implemented solutions to mitigate the impact of Medicare hospice caps that constrained its income potential during 2025. Analysts anticipate the firm will beat guidance for the fourth quarter of 2026 and the full fiscal year.
Timeline
Medicare hospice caps limited income during 2025.
Chemed stock closed at its previous price point on October 26, 2026.
The analyst note was released to clients on October 27, 2026.
Jefferies officially upgraded the stock on October 28, 2026.
Analysts expect an earnings beat in Q4 2026.
Money Landscape
Chemed's 16% stock price increase over the past year trails the 23% rise seen in the broader S&P 500 healthcare sector. The recent upgrade reflects analyst optimism that the company is emerging from a period where its income growth was hampered by regulatory caps.
Investors currently holding Chemed shares may see changes in market valuation following the raised price target and analyst upgrade. As with any equity, those evaluating their portfolio should consult with a qualified financial advisor before making any changes to their holdings.
The takeaway
The upgrade from Jefferies signals renewed confidence in Chemed's operational recovery after regulatory headwinds stalled growth. Investors should continue to monitor upcoming quarterly reports to see if the company successfully meets the anticipated guidance for the remainder of 2026.
Further reading
For more on market analysis and research, visit our Stock Picks section.
Source note: This article includes information reported by CNBC.
Live Poll
Do you rely on analyst stock upgrades when making your own investment decisions?
